Market Data
Market Cap₹7,822.71 Cr.
52W High₹744.75
Current Price₹737.6
52W Low₹118.35
Down from 52W High1 %
Face Value₹1
Performance
ROCE17.48 %
ROE11.42 %
EPS (TTM)₹4.73
EPS Prev Qtr₹3.37
EPS Last Year₹2.58
EBITDA Qtr₹66.46 Cr.
Book Value₹112
Financial Health
Debt/Equity0
Debt/Profit0.02
Total Assets₹1,492.413 Cr.
Dividend Yield0.14 %
Promoter Holding35.01 %
Earning Power10.98 %
Valuation
Stock P/E57.27
Industry P/E33.81
Price to Book6.56
Price to Sales7.78
Graham Number₹180.51
Key Metrics
__derived
1
Dividend/Share
₹0.5
Face Value
₹1
About Bliss GVS Pharma Ltd
Healthcare · Pharmaceuticals
Bliss GVS Pharma Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹7,822.71 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 17.48%, indicating efficient use of capital.
- The company is debt-free with a Debt to Equity ratio of 0, reducing financial risk.
- The company has a promoter holding of 35.01%, suggesting strong management control.
Weaknesses
- The P/E ratio of 52.79 is relatively high, indicating the stock may be overvalued.
- The dividend yield is very low at 0.15%, which may not attract income-focused investors.
- The P/B ratio of 6.04 suggests the market values the company at a premium over its book value.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 37.6% YoY, Profit grew 15.8% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 207.47 | 244.4 | 218.25 | 256.99 | 285.58 |
| ↳ QoQ Growth | - | +17.8% | -10.7% | +17.8% | +11.1% |
| Expenses | 186.06 | 209.18 | 191.81 | 221.22 | 219.11 |
| Operating Profit | 21.4 | 35.22 | 26.44 | 35.77 | 66.46 |
| OPM % | 10.31% | 14.41% | 12.11% | 13.92% | 23.27% |
| Other Income | 47.17 | 8.46 | 18.46 | 11.16 | 9.6 |
| Interest | 5.47 | 3.04 | 1.49 | 2.01 | 0.58 |
| Depreciation | 8.2 | 8.26 | 8.35 | 8.67 | 9.94 |
| EBITDA | 29.6 | 43.48 | 34.79 | 44.44 | 76.4 |
| EBITDA Margin % | 14.27% | 17.79% | 15.94% | 17.29% | 26.75% |
| Profit Before Tax | 63.11 | 40.63 | 40.9 | 44.95 | 75.48 |
| Tax % | 29.71% | 29.63% | 39.41% | 17.69% | 31.94% |
| Net Profit | 44.36 | 28.59 | 24.78 | 37 | 51.37 |
| ↳ QoQ Growth | - | -35.6% | -13.3% | +49.3% | +38.8% |
| EPS | 4.08 | 2.58 | 2.2 | 3.37 | 4.73 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 927.11 | 1005.22 |
| Expenses | 808.27 | 841.32 |
| Operating Profit | 118.83 | 163.89 |
| OPM % | 12.82% | 16.3% |
| Other Income | 85.25 | 47.68 |
| Interest | 12.01 | 7.12 |
| Depreciation | 33.48 | 35.22 |
| Profit Before Tax | 189.59 | 201.96 |
| Tax % | 28.94% | 29.82% |
| Net Profit | 134.73 | 141.74 |
| EPS | 12.23 | 12.88 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
402.45%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
11.88%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10.54 | 10.5789 |
| Reserves | 1039.84 | 1182.3207 |
| Borrowings | 88.1 | 2.93 |
| Other Liabilities | 162.81 | 296.58 |
| Total Liabilities | 1301.29 | 1492.4133 |
| Fixed Assets | 397.69 | 458.6061 |
| CWIP | 20.71 | 6.0463 |
| Investments | 4.38 | 5.65 |
| Other Assets | 878.51 | 1022.11 |
| Total Assets | 1301.29 | 1492.4133 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 138.7178 |
| Cash from Investing Activity | -38.2796 |
| Cash from Financing Activity | -89.2107 |
| Net Cash Flow | 11.2275 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 586.4 |
| ROCE % | 7.98% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 35.39% | 35.36% | 35.36% | 35.01% |
| FIIs % | 13.27% | 14.54% | 10.45% | 8.07% |
| DIIs % | 5.98% | 5.78% | 5.04% | 9.47% |
| Public % | 32.85% | 31.48% | 32.6% | 29.77% |
| No. of Shareholders | 44,461 | 43,380 | 44,874 | 46,767 |
Major Shareholders (>1%)
- Narsimha Shibroor KamathPromoter and Promoter Group30.58%
- Gulbarga Trading And Investment PrivatePublic Shareholding5.50%
- Arjun Gautam Ashra .Public Shareholding4.76%
- Clarus Capital IPublic Shareholding3.51%
As of 2026-06-30View all shareholders →